NCT07672236 Bupivacaine Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07672236—A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. (BEAM-Pain)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07672236 is a hot trial to watch

Pain is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07672236 is notable because it evaluates Bupivacaine in a Phase 3 design while Oral pain will be measured using a 0-10 numerical rating scale (0 = no pain, 10 = worst possible pain). Participants will rate their pain before taking the study treatment and at several time points after dosing. These measurements will be combined to assess how pain changes over time after treatment and to compare BupiZenge with lidocaine. serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment. Planned enrollment of 150 participants across Sweden, Norway, Denmark, Germany shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Oral pain will be measured using a 0-10 numerical rating scale (0 = no pain, 10 = worst possible pain). Participants will rate their pain before taking the study treatment and at several time points after dosing. These measurements will be combined to assess how pain changes over time after treatment and to compare BupiZenge with lidocaine. (From before to 3 hours after dose, on the last day of radiotherapy)
• Secondary: Oral pain will be measured using a 0-10 numerical rating scale (0 = no pain, 10 = worst possible pain). Participants will rate their pain before taking the study treatment and at several time points after dosing. These measurements will be combined to assess how pain changes over time after treatment and to compare BupiZenge with lidocaine. (From before dose to 3 hours after dose, on Day 1 and during Weeks 1 to 3)
• Secondary: Oral pain will be measured using a 0-10 numerical rating scale (0 = no pain, 10 = worst possible pain). Patients who achieve at least a 30% reduction in their overall pain will be considered responders. Pain scores will be collected before dosing and at several time points after dosing, and combined to assess the overall change in pain over time. The proportion of responders will be compared between BupiZenge and lidocaine. (From before dose to 3 hours after dose, on the last day of radiotherapy and during Weeks 1 to 3)
• Secondary: Oral pain will be measured using a 0-10 numerical rating scale (0 = no pain, 10 = worst possible pain). Weekly pain changes will be compared between BupiZenge and lidocaine. (From before dose to 15 minutes after dose during the week before end of radiotherapy and during Weeks 1 to 3 after radiotherapy)
• Secondary: Oral pain will be measured using a 0-10 numerical rating scale (0 = no pain, 10 = worst possible pain). Weekly pain changes will be compared between BupiZenge and lidocaine. (From before dose to 60 minutes after dose during the week before end of radiotherapy and during Weeks 1 to 3 after radiotherapy)

Benchmark readouts in the surrounding field

• Superficial parasternal intercostal plane block with ropivacaine versus placebo for opioid exposure after cardiac surgery (EPOCH CardioLink-10): a multicentre, double-blind, randomised trial (Phase 3): Opioid Consumption(72 hour): Difference (LS Mean) = -20.7(95.0% CI, -39.0 to -2.3), P-Value = 0.027; Opioid Consumption(72 hour): Difference (LS Mean) = -20.7(95.0% CI, -39.0 to -2.3), P-Value = 0.027
• A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 in the Treatment of Pain and Symptoms of Knee Osteoarthritis (Phase 3): Change From Baseline in the WOMAC Pain Sub-score in the Target Knee at Week 2.(Mean) = -19.64 Scores on a scale (95% Confidence Interval, -21.66 to -17.61); Change From Baseline in the WOMAC Pain Sub-score in the Target Knee at Week 2.(Mean) = -21.17 Scores on a scale (95% Confidence Interval, -23.22 to -19.12)
• Comparative Efficacy of Two Different Oral Dosage Forms of Acetaminophen for Post-operative Analgesia in Bariatric Surgery Patients (Phase 2): Pain Control(Mean) = 3.8 Units on a scale (0 to 10) (Standard Deviation, 1.5); Pain Control(Mean) = 3.6 Units on a scale (0 to 10) (Standard Deviation, 1.3)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Bupivacaine (Approved; SCNA)

Company & Deal Intelligence context: OncoZenge AB — Sweden — http://www.oncozenge.se

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

NCT07672236 is a focused lens on Pain development. Its value will be determined by whether Bupivacaine can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.